Vivos Therapeutics, a medical technology company specializing in the treatment of dentofacial abnormalities and sleep apnea, has filed a prospectus with the SEC detailing the resale of shares by a selling stockholder. The selling stockholder, V-CO Investors LLC, affiliated with private equity firm New Seneca Partners, Inc., is offering 169,498 shares of common stock, 3,050,768 shares issuable upon exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon exercise of a Common Stock Purchase Warrant. These securities were acquired as part of a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares, but may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS'. The selling stockholder may sell the shares through various methods including brokerage transactions, block trades, or directly to purchasers. The timing and amount of any sale are at the discretion of the selling stockholder.

Vivos Therapeutics, a medical technology company specializing in the treatment of dentofacial abnormalities and sleep apnea, has filed a prospectus with the SEC detailing the resale of shares by a selling stockholder. The selling stockholder, V-CO Investors LLC, affiliated with private equity firm New Seneca Partners, Inc., is offering 169,498 shares of common stock, 3,050,768 shares issuable upon exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon exercise of a Common Stock Purchase Warrant. These securities were acquired as part of a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares, but may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS'. The selling stockholder may sell the shares through various methods including brokerage transactions, block trades, or directly to purchasers. The timing and amount of any sale are at the discretion of the selling stockholder.